Want to see AU:ALA full AI Analyst Report?
ALA Stock Chart & Stats
AU$0.08
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.08
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.13
Previous CloseN/A
Volume194.12K
Average Volume (3M)1.58M
Market Cap
AU$79.78M
Enterprise ValueAU$66.46M
Total Cash (Recent Filing)AU$19.37M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,208,783,700
10 Day Avg. Volume1,549,358
30 Day Avg. Volume1,578,675
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)5.47
Price to Sales (P/S)806.87
P/FCF Ratio-14.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$6.70M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet (minimal Debt)Having essentially no debt materially reduces financial risk and interest burden, giving management flexibility to fund R&D and manage trial timelines without cash drain from interest. This durable capital structure supports survival through long development cycles typical in biotech.
Strengthened Equity BaseA materially larger equity base provides a longer runway and a stronger capital buffer to absorb ongoing losses and fund clinical programs. This reduces immediate refinancing pressure and supports continued R&D investment without instant reliance on dilutive raises.
Specialized Cell‑therapy R&D FocusA focused platform in iNKT and CAR cell therapies is a durable strategic asset: specialized expertise and proprietary approaches can create high barriers to entry, attract partnerships, and deliver outsized long-term value if clinical translation succeeds.
Bears Say
Persistent Operating LossesSustained operating losses erode capital and force ongoing funding rounds, which can dilute shareholders and divert management attention. Over a multi‑month horizon, persistent losses constrain the firm's ability to scale programs and increase execution risk for clinical milestones.
Negative Cash Generation; Not Self‑fundingConsistently negative operating and free cash flow means the company must secure external capital to continue operations and trials. This creates execution risk, potential dilution, and timing uncertainty that can impede sustained R&D progress and long-term program continuity.
Volatile, Minimal Revenue BaseA very small, volatile revenue base offers limited operational cushioning and shows weak commercialization traction. Over 2–6 months this structural weakness increases dependence on external funding and makes long-term margin improvement and predictable cash generation unlikely.
Arovella Therapeutics Limited News
ALA FAQ
What was Arovella Therapeutics Limited’s price range in the past 12 months?
Arovella Therapeutics Limited lowest share price was AU$0.06 and its highest was AU$0.13 in the past 12 months.
What is Arovella Therapeutics Limited’s market cap?
Arovella Therapeutics Limited’s market cap is AU$79.78M.
When is Arovella Therapeutics Limited’s upcoming earnings report date?
Arovella Therapeutics Limited’s upcoming earnings report date is Sep 02, 2026 which is in 64 days.
How were Arovella Therapeutics Limited’s earnings last quarter?
Arovella Therapeutics Limited released its earnings results on Feb 19, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is Arovella Therapeutics Limited overvalued?
According to Wall Street analysts Arovella Therapeutics Limited’s price is currently Overvalued.
Does Arovella Therapeutics Limited pay dividends?
Arovella Therapeutics Limited does not currently pay dividends.
What is Arovella Therapeutics Limited’s EPS estimate?
Arovella Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arovella Therapeutics Limited have?
Arovella Therapeutics Limited has 1,208,783,700 shares outstanding.
What happened to Arovella Therapeutics Limited’s price movement after its last earnings report?
Arovella Therapeutics Limited reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.706%.
Which hedge fund is a major shareholder of Arovella Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:ALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arovella Therapeutics Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ALA Sentiment 90%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$13.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.82%
12-Months-Change
Fundamentals
Return on Equity
-40.65%
Trailing 12-Months
Asset Growth
60.08%
Trailing 12-Months
Company Description
Arovella Therapeutics Limited
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.
Technical Analysis
Amplia Therapeutics
―
Alterity Therapeutics
―
Proteomics International Laboratories Ltd.
―
EZZ Life Science Holdings Ltd.
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---